STOK
STOK clinical trials: Stoke Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Stoke Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
STOK on the catalyst calendar · STOK registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Mar 2027Sponsor estimate | NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeStoke Therapeutics, Inc · Dravet Syndrome | STOKLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Mar 31, 2029Sponsor estimate | NCT04740476An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeStoke Therapeutics, Inc · Dravet Syndrome | STOKLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Nov 14, 2023Actual | NCT04442295An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromeStoke Therapeutics, Inc · Dravet Syndrome | STOKLead | Phase 1/Phase 2 | Completed | Locked | Locked | Locked |
- Primary completion Mar 2027Sponsor estimatePhase 3NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeStoke Therapeutics, Inc · Dravet SyndromeActive, not recruitingSTOKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2029Sponsor estimatePhase 2NCT04740476An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeStoke Therapeutics, Inc · Dravet SyndromeActive, not recruitingSTOKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2023ActualPhase 1/Phase 2NCT04442295An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromeStoke Therapeutics, Inc · Dravet SyndromeCompletedSTOKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner